STOCK TITAN

Fundamental Research Corp Updates Investment Analysis Coverage on THC Biomed

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

THC BioMed Intl Ltd. announced on Feb. 17, 2021 that Fundamental Research Corp. has updated its independent investment analysis coverage on the company, which includes a change of valuation. THC BioMed states that this update is for informational purposes only and does not endorse the content of the report. The company operates under the Cannabis Act as a licensed producer of medical and recreational cannabis, focusing on cultivation and sales across various forms of cannabis products.

Positive
  • Independent investment analysis update from Fundamental Research Corp.
  • Positioned in the rapidly growing medical cannabis industry.
Negative
  • No endorsement of the report's contents by THC BioMed.
  • Forward-looking statements include uncertainty about future industry positioning.

THC.CSE
THCBF
 - OTC
TFHD.F

VANCOUVER, BC, Feb. 17, 2021 /PRNewswire/ - THC BioMed Intl Ltd. ("THC BioMed" or the "Company") discloses that Fundamental Research Corp. has updated its independent investment analysis coverage on THC BioMed with a note and change of valuation.

Fundamental Research Corp. is an issuer-paid independent research house. THC BioMed notes this development for information only and does not endorse the contents of Fundamental Research Corp.'s report.

About THC

THC BioMed is a Cannabis Act Licensed Producer of medical and recreational cannabis. It is licensed to cultivate and sell dried, extract, edible and topical cannabis. The Company is on the leading edge of scientific research and the development of products and services related in the medical cannabis industry. Management believes THC BioMed is well-positioned to be in the forefront of this rapidly growing industry.

Forward-Looking Information:

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of THC BioMed.  Forward-looking information is based on certain key expectations and assumptions made by the management of THC BioMed.  In some cases, you can identify forward-looking statements by the use of words such as "will," "may," "would," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "could" and variations of these terms and similar expressions, or the negative of these terms or similar expressions.  Forward-looking statements in this release are made as of the date of this press release and include that THC BioMed will be on the forefront of this rapidly growing industry. Although THC BioMed believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because THC BioMed can give no assurance that they will prove to be correct. THC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fundamental-research-corp-updates-investment-analysis-coverage-on-thc-biomed-301229761.html

SOURCE THC BioMed

FAQ

What does the update from Fundamental Research Corp. indicate for THCBF?

The update provides an independent investment analysis and a change of valuation for THC BioMed.

When was the press release about THCBF issued?

The press release was issued on Feb. 17, 2021.

What type of products does THC BioMed produce?

THC BioMed produces medical and recreational cannabis and is licensed to cultivate and sell various cannabis products.

Does THC BioMed endorse the content of Fundamental Research Corp.'s report?

No, THC BioMed states it does not endorse the contents of the report.

What does THC BioMed's forward-looking statement suggest?

It suggests potential growth in the industry but includes uncertainties that could affect its future positioning.

THC BIOMED INTL LTD ORD

OTC:THCBF

THCBF Rankings

THCBF Latest News

THCBF Stock Data

2.40M
116.35M
29.03%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Kelowna